Biotechnology company GeoVax Labs will share critical clinical research findings at two significant medical conferences in April 2025, highlighting potential breakthroughs in vaccine development and cancer therapy.
At the World Vaccine Congress in Washington, DC, Dr. Don J. Diamond from City of Hope Comprehensive Cancer Center will present Phase 2b study results of GeoVax's multi-antigen COVID-19 vaccine candidate GEO-CM04S1. The presentation will compare the experimental vaccine to currently approved COVID-19 vaccines, potentially offering insights for immunocompromised patient populations.
The American Association of Cancer Research conference in Chicago will feature a presentation by Dr. J. Marc Pipas on Gedeptin, a viral-vectored gene-directed prodrug therapy targeting solid tumors. This research represents a novel approach to cancer treatment, focusing on needle-accessible tumors.
These conference presentations underscore GeoVax's ongoing research in two critical medical domains: infectious disease prevention and cancer treatment. The company's COVID-19 vaccine candidate is being evaluated for patients with specific medical conditions, including those with hematologic cancers and chronic lymphocytic leukemia, where current vaccines may have limited efficacy.
The scientific community will be closely watching these presentations, as they could potentially reveal innovative strategies for addressing complex medical challenges in vaccine development and oncological treatments.
